By: Adam Feuerstein | 07/25/14 - 11:30 AM EDT
Exactly four weeks have passed since
(MNKD) secured FDA approval for its inhaled insulin device Afrezza. But with no announcement from
MannKind executives about a partnership necessary to sell Afrezza, the company's stock is sliding down hill.
MNKD data by YCharts
Mannkind executives may be forced to say something about the state of Afrezza partnership discussions very soon, even if no deal is in place. That's because MannKind must report second-quarter financials before the end of the second week in August. Historically, MannKind reports second-quarter financials in early August. Last year's reporting date was Aug. 9; the year before, it was Aug. 7. MannKind has not announced a date for the upcoming second quarter financials yet, but it must happen by Aug. 15, per SEC reporting rules.
If MannKind is close to signing an Afrezza partnership, the company is almost certainly pushing very hard to get that deal closed before it must report second-quarter financials. The alternative is ugly. Holding a conference call in early or middle August with nothing concrete to say about an Afrezza deal would be damaging to MannKind. Investors are growing tired of optimistic partnership talk that goes nowhere.
At one point earlier this summer, MannKind (sort of) promised an Afrezza partnership 6-8 weeks after FDA approval. Soon after, MannKind tried to walk back that expectation. Afrezza was approved on June 27, so 6-8 weeks out is Aug. 8 through Aug. 22, which overlaps with the requirement to report second-quarter results.
The waiting is hard, but one way or another, we should hear something more definitive from MannKind about an Afrezza deal (or the lack of one) within weeks, at the latest.
10/22/14 - 11:52 AM EDT
10/22/14 - 08:39 AM EDT
10/21/14 - 09:29 AM EDT
10/20/14 - 10:56 AM EDT
10/15/14 - 04:07 PM EDT
10/24/14 - 14:29 PM EDT
10/24/14 - 11:30 AM EDT
10/23/14 - 12:59 PM EDT
10/23/14 - 11:52 AM EDT
10/23/14 - 11:41 AM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.